Search - tctmd.com

Displaying 101 - 110 of 110

Sort: Relevancy | Date

News Daily News

ESC Offers Recommendations on Use of New Oral Anticoagulants

Yael L. Maxwell

May 03, 2013

News Daily News

Los betabloqueadores reducen la mortalidad a largo plazo en pacientes de alto riesgo de STEMI

Yael L. Maxwell

December 13, 2012

News Daily News

Beta-Blockers Reduce Long-term Mortality in High-Risk STEMI Patients

Yael L. Maxwell

December 13, 2012

News Daily News

Watchman Works Just as Well Without Warfarin-Protected Transition

June 01, 2012

News Industry News

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

May 11, 2012

News Industry News

New Data From Landmark Study Shows Cost-Effectiveness of Medtronic Life-Saving CRT-D Therapy in Mildly Symptomatic Heart Failure Patients

May 11, 2012

News Industry News

Bayer cooperates with Ludwig Boltzmann Institute for Translational Heart Failure Research

November 08, 2011

News Industry News

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

November 04, 2011

News Industry News

Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial

September 29, 2011

News Industry News

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

September 08, 2011

Advertisement

ESC Offers Recommendations on Use of New Oral Anticoagulants

Los betabloqueadores reducen la mortalidad a largo plazo en pacientes de alto riesgo de STEMI

Beta-Blockers Reduce Long-term Mortality in High-Risk STEMI Patients

Watchman Works Just as Well Without Warfarin-Protected Transition

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

New Data From Landmark Study Shows Cost-Effectiveness of Medtronic Life-Saving CRT-D Therapy in Mildly Symptomatic Heart Failure Patients

Bayer cooperates with Ludwig Boltzmann Institute for Translational Heart Failure Research

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content